- Home
- AXSM
as of 01-06-2026 3:56pm EST
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 9.0B | IPO Year: | 2015 |
| Target Price: | $177.50 | AVG Volume (30 days): | 666.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 20 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $79.19 - $184.40 | Next Earning Date: | 02-17-2026 |
| Revenue: | $561,263,000 | Revenue Growth: | 65.83% |
| Revenue Growth (this year): | 66.4% | Revenue Growth (next year): | 56.13% |
AI-Powered AXSM Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Axsome Therapeutics Inc. (AXSM)
Chief Executive Officer
Avg Cost/Share
$148.18
Shares
10,558
Total Value
$1,564,484.44
Owned After
7,229
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$146.94
Shares
20,163
Total Value
$2,962,751.22
Owned After
7,229
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$144.59
Shares
49,252
Total Value
$7,121,346.68
Owned After
7,229
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$134.49
Shares
21,775
Total Value
$2,928,519.75
Owned After
7,229
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$133.79
Shares
50,459
Total Value
$6,750,909.61
Owned After
7,229
SEC Form 4
Chief Executive Officer
Avg Cost/Share
$132.34
Shares
91,705
Total Value
$12,136,239.70
Owned After
7,229
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| TABUTEAU HERRIOT | AXSM | Chief Executive Officer | Dec 4, 2025 | Sell | $148.18 | 10,558 | $1,564,484.44 | 7,229 | |
| TABUTEAU HERRIOT | AXSM | Chief Executive Officer | Dec 3, 2025 | Sell | $146.94 | 20,163 | $2,962,751.22 | 7,229 | |
| TABUTEAU HERRIOT | AXSM | Chief Executive Officer | Dec 2, 2025 | Sell | $144.59 | 49,252 | $7,121,346.68 | 7,229 | |
| TABUTEAU HERRIOT | AXSM | Chief Executive Officer | Nov 5, 2025 | Sell | $134.49 | 21,775 | $2,928,519.75 | 7,229 | |
| TABUTEAU HERRIOT | AXSM | Chief Executive Officer | Nov 4, 2025 | Sell | $133.79 | 50,459 | $6,750,909.61 | 7,229 | |
| TABUTEAU HERRIOT | AXSM | Chief Executive Officer | Nov 3, 2025 | Sell | $132.34 | 91,705 | $12,136,239.70 | 7,229 |
Compare AXSM vs Leading Stocks
See how AXSM stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "AXSM Axsome Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.